重视药物相互作用，助力 CDK4/6i 一线治疗疗效、安全性获益 | 2024 ESMO BC

文章预览

本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面 ✩ 本文仅供医疗卫生等专业人士参考 审批码：KIS0026637-63376，有效期至2025-06-18，资料过期视同作废 内容审核：唐颖 项目审核：于轩 参考文献 [1]Drug-drug interactions and their impact on clinical outcomes and adverse events in hormone receptor (HR)+/HER2- advanced breast cancer patients treated with ribociclib + letrozole: Insights from the BioltaLEE trial. 2024 ESMO BC 211P. [2]ZHANG P, ZHANG Q, TONG Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2023, 24(6): 646-57. [3]Finn Rs, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) vers ………………………………